As liquid chromatography–mass spectrometry (LC/MS) becomes more widely adopted for the analysis of biotherapeutics, researchers continue to discover new and advanced uses for this technology.
Brought to you by
REGISTER TODAY
As liquid chromatography–mass spectrometry (LC/MS) becomes more widely adopted for the analysis of biotherapeutics, researchers continue to discover new and advanced uses for this technology.
In this webinar, Ben Niu, Ph.D., Scientist II, AstraZeneca, explains how his company is implementing novel LC/MS workflows on a fully automated platform to improve systematic product analysis and throughput.
Dr Niu will demonstrate how AstraZeneca’s high-throughput multi-attribute method (MAM) workflows provide more information and dramatic time savings. He will show how MAM has the potential to replace traditional methods, such as released glycans, charge variant and sequence variant analysis, with correlated results to demonstrate comparability.
He will focus on how new peak detection provides critical information that was previously unavailable, extending product and method knowledge. In addition, Dr Niu will describe how the marriage of ion exchange chromatography (IEX) and MS within MAM provides accelerated characterization of product charge heterogeneity.
By attending this webinar, you will learn:
Speaker Information:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
Email: privacy@technologynetworks.com
© 2020 Technology Networks, All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy